[EN] COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING β-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA [FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES D'INHIBITION SÉLECTIVE DES BETA-GLUCURONIDASES ET D'ATTÉNUATION DES EFFETS SECONDAIRES ASSOCIÉS À UNE DIARRHÉE PROVOQUÉE PAR UN TRAITEMENT MÉDICAMENTEUX
[EN] COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING β-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA [FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES D'INHIBITION SÉLECTIVE DES BETA-GLUCURONIDASES ET D'ATTÉNUATION DES EFFETS SECONDAIRES ASSOCIÉS À UNE DIARRHÉE PROVOQUÉE PAR UN TRAITEMENT MÉDICAMENTEUX
A facile and efficient synthesis of substituted quinolin-2(1H)-ones is developed via intramolecular cyclization of penta-2,4-dienamides mediated by concentrated H2SO4 (98%), and a mechanism involving the formation of a dicationic superelectrophile, and subsequent intramolecular nucleophilic cyclization reactions is proposed.
COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING Beta- -GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA
申请人:Symberix, Inc.
公开号:EP3710003A1
公开(公告)日:2020-09-23
COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA
申请人:SYMBERIX, INC.
公开号:US20210094917A1
公开(公告)日:2021-04-01
The present disclosure describes compounds and compositions that inhibit β-glucuronidase activity, and methods for attenuating the side effects of one or more drugs and improving the efficacy of drugs by administration of selective β-glucuronidase inhibitors.
[EN] COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING β-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES D'INHIBITION SÉLECTIVE DES BETA-GLUCURONIDASES ET D'ATTÉNUATION DES EFFETS SECONDAIRES ASSOCIÉS À UNE DIARRHÉE PROVOQUÉE PAR UN TRAITEMENT MÉDICAMENTEUX
申请人:SYMBERIX INC
公开号:WO2019051185A1
公开(公告)日:2019-03-14
The present disclosure describes compounds and compositions that inhibit β-glucuronidase activity, and methods for attenuating the side effects of one or more drugs and improving the efficacy of drugs by administration of selective β-glucuronidase inhibitors.